This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aartsma-Rus A, Janson AA et al. (2004) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74(1): 83-92
Andreassi C, Jarecki J et al. (2001) Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 10 (24): 2841-9
Baron-Delage S, Abadie A et al. (2000) Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol Med 6(11): 957-968
Black DL (2000) Protein diversity from alternative splicing: a challenge for bioin-formatics and post-genome biology. Cell 103(3): 367-370
Black DL (2003) Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72: 291-336
Bracco L, Kearsey J (2003) The relevance of alternative RNA splicing to pharma-cogenomics. Trends Biotechnol 21(8): 346-353
Brahe C, Vitali T et al. (2005) Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 13(2): 256-259
Bremmer-Bout M, Aartsma-Rus A et al. (2004) Targeted exon skipping in trans-genic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 10(2): 232-40
Brichta L, Hofmann Y et al. (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12(19): 2481-2489
Bruno IG, Jin W et al. (2004) Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet 13 (20): 2409-2420
Buratti E, Baralle FE (2005) Another step forward for SELEXive splicing. Trends Mol Med 11(1): 5-9
Buratti E, Baralle FE et al. (2003) Can a “patch” in a skipped exon make the pre-mRNA splicing machine run better? Trends Mol Med 9(6): 229-232; discussion 233-234
Caceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control mecha-nisms and involvement in human disease. Trends Genet 18(4): 186-193
Carstens RP, Eaton JV et al. (1997) Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 15(25): 3059-3065
Cartegni L, Chew SL et al. (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3(4): 285-298
Cartegni L, Krainer AR (2003) Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 10(2): 120-125
Celotto AM, Graveley BR (2002) Exon-specific RNAi: a tool for dissecting the functional relevance of alternative splicing. Rna 8(6): 718-724
Chandrasekharan NV, Dai H et al. (2002) COX-3 a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning structure and expression. Proc Natl Acad Sci USA 99(21): 13926-13931
Chang JG, Hsieh-Li HM et al. (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 98(17): 9808-9813
Chao H, Mansfield SG et al. (2003) Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med 9(8): 1015-1019
Cooper TA (2005) Alternative splicing regulation impacts heart development. Cell 120 (1): 1-2
Coovert DD, Le TT et al. (1997) The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 6(8): 1205-1214
Crooke ST (2004a) Antisense strategies. Curr Mol Med 4(5): 465-487
Crooke ST (2004b) Progress in antisense technology. Annu Rev Med 55: 61-95
Cui JG, Kuroda H et al. (2004) Cyclooxygenase-3 gene expression in Alzheimer hippocampus and in stressed human neural cells. Neurochem Res 29 (9): 1731-1737
Daoud R, Mies G et al. (2002) Ischemia induces a translocation of the splicing factor tra2-beta 1 and changes alternative splicing patterns in the brain. J Neurosci 22(14): 5889-5899
De Angelis FG, Sthandier O et al. (2002) Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc Natl Acad Sci USA 99(14): 9456-9461
De Sandre-Giovannoli A, Bernard R et al. (2003) Lamin a truncation in Hutchinson-Gilford progeria. Science 300(5628): 2055
Deidda G, Rossi N et al. (2003) An archaeal endoribonuclease catalyzes cis- and trans-nonspliceosomal splicing in mouse cells. Nat Biotechnol 21(12): 1499-1504
Dominski Z, Kole R (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 90(18): 8673-8677
Dunckley MG, Manoharan M et al. (1998) Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7(7): 1083-1090
Dykxhoorn DM, Novina CD et al. (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4(6): 457-467
Eperon IC, Muntoni F (2003) Response to Buratti et al.: Can a ‘patch’ in a skipped exon make the pre-mRNA splicing machine run better? Trends Mol Med 9 (6): 233-234
Eriksson M, Brown WT et al. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423(6937): 293-298
Faustino NA, Cooper TA (2003) Pre-mRNA splicing and human disease. Genes Dev 17(4): 419-437
Friedman KJ, Kole J et al. (1999) Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem 274(51): 36193-36199
Garcia-Blanco M A (2003) Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing. J Clin Invest 112(4): 474-480
Garcia Blanco M (2005) Making antisense of splicing. Current Opinion in Molecular Therapeutics, in press
Garcia-Blanco M A, Baraniak AP et al. (2004) Alternative splicing in disease and therapy. Nat Biotechnol 22(5): 535-546
Gorman L, Suter D et al. (1998) Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci USA 95(9): 4929-4934
Goyenvalle A, Vulin A et al. (2004) Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306(5702): 1796-1799
Gunthert U, Stauder R et al. (1995) Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 24: 19-42
Helmken C, Hofmann Y et al. (2003) Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum Genet 114(1): 11-21
Hommel JD, Sears RM et al. (2003) Local gene knockdown in the brain using viral-mediated RNA interference. Nat Med 9(12): 1539-1544
Hong M, Zhukareva V et al. (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282(5395): 1914-1917
Hutton M, Lendon CL et al. (1998) Association of missense and 5′-splice-site muta-tions in tau with the inherited dementia FTDP-17. Nature 393(6686): 702-705
Johnson JM, Castle J et al. (2003) Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302(5653): 2141-2144
Kalbfuss B, Mabon SA et al. (2001) Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem 276(46): 42986-42993
Kalnina Z, Zayakin P et al. (2005) Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42(4): 342-357
Karras JG, Maier MA et al. (2001) Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-alpha chain. Biochemistry 40(26): 7853-7859
Kashima T, Manley JL (2003) A negative element in SMN2 exon 7 inhibits splic-ing in spinal muscular atrophy. Nat Genet 34(4): 460-463
Khoo B, Akker SA et al. (2003) Putting some spine into alternative splicing. Trends Biotechnol 21(8): 328-330
Kole R, Vacek M et al. (2004) Modification of alternative splicing by antisense therapeutics. Oligonucleotides 14(1): 65-74
Kole R, Williams T et al. (2004) RNA modulation repair and remodeling by splice switching oligonucleotides. Acta Biochim Pol 51(2): 373-378
Lacerra G, Sierakowska H et al. (2000) Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA 97(17): 9591-9596
Liu S, Asparuhova M et al. (2004) Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Res 32 (12): 3752-3759
Liu X, Jiang Q et al. (2002) Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol 20(1): 47-52
Lorson CL, Hahnen E et al. (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96 (11): 6307-6311
Lu QL, Mann CJ et al. (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9 (8): 1009-1014
Lu QL, Rabinowitz A et al. (2005) Systemic delivery of antisense oligoribonu-cleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102(1): 198-203
Maniatis T, Tasic B (2002) Alternative pre-mRNA splicing and proteome expan-sion in metazoans. Nature 418(6894): 236-243
Mann CJ, Honeyman K et al. (2001) Antisense-induced exon skipping and synthe-sis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 98(1): 42-47
Mansfield SG, Chao H et al. (2004) RNA repair using spliceosome-mediated RNA trans-splicing. Trends Mol Med 10(6): 263-268
Mercuri E, Bertini E et al. (2004) Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 14(2): 130-135
Millar DS, Lewis MD et al. (2003) Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for indi-viduals with short stature. Hum Mutat 21(4): 424-440
Modrek B, Lee CJ (2003) Alternative splicing in the human mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat Genet 34(2): 177-180
Muntoni F, Torelli S et al. (2003) Dystrophin and mutations: one gene several pro-teins multiple phenotypes. Lancet Neurol 2(12): 731-740
Muraki M, Ohkawara B et al. (2004) Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 279(23): 24246-24254
Musunuru K (2003) Cell-specific RNA-binding proteins in human disease. Trends Cardiovasc Med 13(5): 188-195
Nalla VK, Rogan PK (2005) Automated splicing mutation analysis by information theory. Hum Mutat 25(4): 334-342
Pasman Z, Garcia-Blanco MA (1996) The 5′ and 3′ splice sites come together via a three dimensional diffusion mechanism. Nucleic Acids Res 24(9): 1638-1645
Pergolizzi R G, Crystal RG (2004) Genetic medicine at the RNA level: modifica-tions of the genetic repertoire for therapeutic purposes by pre-mRNA transsplicing. C R Biol 327(8): 695-709
Pramono ZA, Takeshima Y et al. (1996) Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynu-cleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 226(2): 445-449
Puttaraju M, Jamison SF et al. (1999) Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat Biotechnol 17(3): 246-252
Puttaraju M, DiPasquale J et al. (2001) Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA trans-splicing. Mol Ther 4 (2): 105-114
Resch A, Xing Y et al. (2004) Evidence for a subpopulation of conserved alterna-tive splicing events under selection pressure for protein reading frame preserva-tion. Nucleic Acids Res 32(4): 1261-1269
Roca X, Sachidanandam R et al. (2003) Intrinsic differences between authentic and cryptic 5′ splice sites. Nucleic Acids Res 31(21): 6321-6333
Rogers CS, Vanoye CG et al. (2002) Functional repair of a mutant chloride chan-nel using a trans-splicing ribozyme. J Clin Invest 110(12): 1783-1789
Ryther RC, McGuinness LM et al. (2003) Disruption of exon definition produces a dominant-negative growth hormone isoform that causes somatotroph death and IGHD II. Hum Genet 113(2): 140-148
Sazani P, Gemignani F et al. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 20(12): 1228-1233
Sazani P, Astriab-Fischer A et al. (2003) Effects of base modifications on antisense properties of 2′-O-methoxyethyl and PNA oligonucleotides. Antisense Nucleic Acid Drug Dev 13(3): 119-128
Scaffidi P, Misteli T (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11(4): 440-445
Shankar P, Manjunath N et al. (2005) The prospect of silencing disease using RNA interference. JAMA 293(11): 1367-1373
Sicinski P, Geng Y et al. (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244(4912): 1578-1580
Sierakowska H, Sambade MJ et al. (1996) Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 93(23): 12840-12844
Simmons DL (2003) Variants of cyclooxygenase-1 and their roles in medicine. Thromb Res 110(5-6): 265-268
Singh NN, Androphy EJ et al. (2004a) An extended inhibitory context causes skip-ping of exon 7 of SMN2 in spinal muscular atrophy. Biochem Biophys Res Commun 315(2): 381-388
Singh NN, Androphy EJ et al. (2004b) In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. Rna 10(8): 1291-1305
Singh NN, Androphy EJ et al. (2004c) The regulation and regulatory activities of alter-native splicing of the SMN gene. Crit Rev Eukaryot Gene Expr 14(4): 271-285
Skordis LA, Dunckley MG et al. (2003) Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 100(7): 4114-4119
Sorek R, Shamir R et al. (2004) How prevalent is functional alternative splicing in the human genome? Trends Genet 20(2): 68-71
Spillantini MG, Murrell JR et al. (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 95 (13): 7737-7741
Stenson PD, Ball EV et al. (2003) Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21(6): 577-581
Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA trans-lation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 75: 285-288
Stevenson M (2004) Therapeutic potential of RNA interference. N Engl J Med 351 (17): 1772-1777
Sullenger BA, Cech TR (1994) Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. Nature 371(6498): 619-622
Sullenger BA, Gilboa E (2002) Emerging clinical applications of RNA. Nature 418(6894): 252-258
Sumner CJ, Huynh TN et al. (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 54(5): 647-654
Tahara M, Pergolizzi RG et al. (2004) Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat Med 10(8): 835-841
Takeshima Y, Wada H et al. (2001) Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscu-lar dystrophy patient. Brain Dev 23(8): 788-790
Taylor JK, Zhang QQ et al. (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 17(11): 1097-1100
Vacek M, Sazani P et al. (2003) Antisense-mediated redirection of mRNA splicing. Cell Mol Life Sci 60(5): 825-833
Venables JP (2004) Aberrant and alternative splicing in cancer. Cancer Res 64(21): 7647-7654
Villemaire J, Dion I et al. (2003) Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides. J Biol Chem 278(50): 50031-50039
Vitarene Study Group (2002) A randomized controlled clinical trial of intravitre-ous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 133(4): 467-474
Wagner E J, Garcia-Blanco MA (2001) Polypyrimidine tract binding protein antag-onizes exon definition. Mol Cell Biol 21(10): 3281-3288
Wall NR, Shi Y (2003) Small RNA: can RNA interference be exploited for therapy? Lancet 362(9393): 1401-1403
Watanabe T, Sullenger BA (2000) RNA repair: a novel approach to gene therapy. Adv Drug Deliv Rev 44 (2-3): 109-118
Wells KE, Fletcher S et al. (2003) Enhanced in vivo delivery of antisense oligonu-cleotides to restore dystrophin expression in adult mdx mouse muscle. FEBS Lett 552(2-3): 145-149
Wilton SD, Lloyd F et al. (1999) Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 9(5): 330-338
Yan G, Fukabori Y et al. (1993) Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13 (8): 4513-4522
Yasumoto H, Matsubara A et al. (2004) Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate 61(3): 236-242
Zamecnik PC and Stephenson ML (1978) Inhibition of Rous sarcoma virus repli-cation and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75: 280-284
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Garcia-Blanco, M.A. (2006). Alternative Splicing: Therapeutic Target and Tool. In: Jeanteur, P. (eds) Alternative Splicing and Disease. Progress in Molecular and Subcellular Biology, vol 44. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34449-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-540-34449-0_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-34448-3
Online ISBN: 978-3-540-34449-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)